These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 29671909

  • 1. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
    Dhillon-Jhattu S, Sprague SM.
    Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
    [Abstract] [Full Text] [Related]

  • 2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 3. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS.
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [Abstract] [Full Text] [Related]

  • 4. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ, González EA.
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [Abstract] [Full Text] [Related]

  • 5. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB, Martin KJ.
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [Abstract] [Full Text] [Related]

  • 6. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
    Mukhin NA, Milovanov YS, Kozlovskaya LV, Dobrosmyslov IA, Milovanova LY.
    Ter Arkh; 2016 Apr; 88(4):41-45. PubMed ID: 27070162
    [Abstract] [Full Text] [Related]

  • 7. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, Kramer HJ.
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [Abstract] [Full Text] [Related]

  • 8. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
    Ureña Torres PA.
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
    [Abstract] [Full Text] [Related]

  • 9. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S.
    Am J Kidney Dis; 2010 May; 55(5):773-99. PubMed ID: 20363541
    [Abstract] [Full Text] [Related]

  • 10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 May; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 11. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F, Del Vecchio L, Violo L, Pontoriero G.
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [Abstract] [Full Text] [Related]

  • 12. Use of phosphate binders in chronic kidney disease.
    Ketteler M, Biggar PH.
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [Abstract] [Full Text] [Related]

  • 13. Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality.
    McCullough PA.
    Cardiorenal Med; 2021 Jul; 11(3):123-132. PubMed ID: 34120113
    [Abstract] [Full Text] [Related]

  • 14. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 15. [Metabolic complications in chronic kidney disease: hyperphosphatemia, hyperkalemia and anemia].
    Hannedouche T, Fouque D, Joly D.
    Nephrol Ther; 2018 Nov 05; 14(6S):6S17-6S25. PubMed ID: 30473062
    [Abstract] [Full Text] [Related]

  • 16. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.
    Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, Fried L.
    Am J Kidney Dis; 2015 Mar 05; 65(3):354-66. PubMed ID: 25465166
    [Abstract] [Full Text] [Related]

  • 17. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification .
    Gross P, Six I, Kamel S, Massy ZA.
    Circ J; 2014 Mar 05; 78(10):2339-46. PubMed ID: 25077548
    [Abstract] [Full Text] [Related]

  • 18. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S, Yamanaka S, Koreeda D, Yashiro M, Shigematsu T.
    Clin Calcium; 2012 Oct 05; 22(10):1557-66. PubMed ID: 23023637
    [Abstract] [Full Text] [Related]

  • 19. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G.
    Expert Opin Pharmacother; 2015 Oct 05; 16(17):2589-99. PubMed ID: 26374200
    [Abstract] [Full Text] [Related]

  • 20. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan 05; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.